Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

United Christian Leadership and Ministry held a community and panel discussion Saturday afternoon on reforming the criminal ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

AI in drug development is a vague term that might mean many things, and today, Owkin is announcing it has enrolled the first patient in a phase 1 study of OKN4395, its “AI-optimized” candidate for ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

Rev. Walker worked closely with King and would be the one to bring King’s Letter from Birmingham Jail to public attention. He was the only one who could understand King’s handwriting.

Lessiter shares personal takeaways at the annual conference that pushes men to take stock of their lives – in business and in ...

PSAT1 and PSRC1 are upregulated in SCLC, with PSRC1 linked to lower survival rates, suggesting potential therapeutic targets. COLEC12, PLLP, and HP are downregulated, affecting immune response and ...

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results from the ADRIATIC trial, in which patients were treated with Imfinzi for ...

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.